La catena delle opzioni mostra i dati chiave delle opzioni azionarie di AvidXchange Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per AvidXchange Holdings..

AvidXchange Holdings (NASDAQ:AVDX) Azioni, Catena delle Opzioni

AvidXchange Holdings

AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.

AvidXchange Holdings, Inc. - Common Stock

AvidXchange Holdings Inc

News

IBKR

Interactive Brokers Files Form 8-K/A Disclosing Revised Operating Results For Q3

EF Hutton analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

Price Target

Analyst Ratings

IMUX

EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target

WIIM

LOGI

Logitech International shares are trading lower. The company reported Q2 financial results.

At a cost of&nbsp;$267 million, the plant is the largest and most important component of the&nbsp;Navajo-Gallup Water Supply Project. When completed, the project will provide water supplies to approximately 250,000 people in 43 Navajo chapters.
Jacobs will design and build the San Juan Lateral Water Treatment Plant to initially treat up to 18.8 million gallons of water per day, with the ability to double the plant&#39;s capacity.

Contracts

Jacobs Says It Is Selected By US Bureau Of Reclamation To Design And Build San Juan Lateral Water Treatment Plant In Northwest New Mexico

Genuine Parts shares are trading lower after the company reported mixed Q3 financial results and cut its FY24 EPS below estimates.

Redburn Atlantic analyst Bingqing Zhu initiates coverage on Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Sell rating and announces Price Target of $165.

Initiation

Redburn Atlantic Initiates Coverage On Hershey with Sell Rating, Announces Price Target of $165

DASH

Fiserv Enters Collaboration With DoorDash To Embed Financial Services Within Digital Platform

Earnings

Earnings Misses

SIFY

Sify Technologies Q2 Sales $122.673M Miss $152.700M Estimate

Canaccord Genuity analyst Carey Macrury downgrades Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) from Buy to Hold.

Downgrades

GATO

Canaccord Genuity Downgrades Gatos Silver to Hold

GE Aerospace shares are trading lower. The company reported Q3 financial results.

GPRK

GeoPark Receives Approval From The Argentinian Securities Regulator To Issue Up To $500M In Debt Securities Over Next Five Years

Keybanc analyst Sophie Karp downgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Overweight to Sector Weight.

Keybanc Downgrades Duke Energy to Sector Weight

Deutsche Bank analyst Koosh Patel maintains AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and raises the price target from $110 to $115.

Deutsche Bank Maintains Buy on AerCap Holdings, Raises Price Target to $115

LXEO

Lexeo Therapeutics Says Interim Data From Ongoing Phase 1/2 Trial Of LX1001 Have Been Selected As Late-breaking Oral Presentation At CTAD Conference

Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.70 by 7.65 percent. This is a 5.17 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $4.952 billion which missed the analyst consensus estimate of $5.048 billion by 1.89 percent. This is a 3.51 percent decrease over sales of $5.132 billion the same period last year.

Earnings Beats

CORRECTION: Kimberly-Clark Q3 2024 Adj. EPS $1.83 Beats $1.70 Estimate, Sales $4.952B Miss $5.048B Estimate

Keybanc analyst Jackson Ader initiates coverage on Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Overweight rating and announces Price Target of $40.

ZETA

Keybanc Initiates Coverage On Zeta Global Holdings with Overweight Rating, Announces Price Target of $40

Deutsche Bank analyst Hillary Cacanando maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $125 to $160.

FTAI

Deutsche Bank Maintains Buy on FTAI Aviation, Raises Price Target to $160

Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN).&nbsp;

BIIB

Biogen Plans To Present Variety Of New Data From Its Felzartamab Clinical Development Program At Kidney Week 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/OGN">52-week low of $10.84</a>.</li>
<li>RSI Value: 28.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">latest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png" alt="" class="wp-image-607146" style="width:757px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)&nbsp;</h3>
<ul>
<li>On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE&#xAE; Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, &#8220;The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours.&#8221; The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.</li>
<li>RSI Value: 28.13</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">trend in ARQT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png" alt="" class="wp-image-606848" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MGRX">low of $36.42</a>.</li>
<li>RSI Value: 29.60</li>
<li>TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">breakout in TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png" alt="" class="wp-image-606851" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.46 per share which met the analyst consensus estimate. This is a 9.8 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $485.862 million which beat the analyst consensus estimate of $482.156 million by 0.77 percent. This is a 6.54 percent increase over sales of $456.024 million the same period last year.

Old National Q3 2024 Adj. EPS $0.46, Inline, Sales $485.862M Beat $482.156M Estimate

Companies in Fin-Tech that would be impacted by a 100 basis point fall in floating rates

Morgan Stanley analyst James Faucette has maintained their neutral stance on AVDX stock, giving a Hold rating on August 20. James Faucette's rating...

A Balanced Outlook on AvidXchange Holdings: Weighing Short-Term Gains Against Long-Term Growth Prospects

Warning: AVDX is at high risk of performing badly

Tracking Lone Pine Capital Portfolio - Q2 2024 Update

Wells Fargo analyst Andrew Bauch maintained a Hold rating on AvidXchange Holdings (AVDX – Research Report) today and set a price target of $10.00. ...

AvidXchange Holdings: Hold Rating Amidst Macroeconomic Challenges and Growth Potential

Analysts have been eager to weigh in on the Technology sector with new ratings on GoDaddy (GDDY – Research Report), AvidXchange Holdings (AVDX – Re...

Analysts Have Conflicting Sentiments on These Technology Companies: GoDaddy (GDDY), AvidXchange Holdings (AVDX) and Super Micro Computer (SMCI)

In a report released yesterday, David Koning from Robert W. Baird maintained a Buy rating on AvidXchange Holdings (AVDX – Research Report), with a ...

AvidXchange: Promising Growth and Strategic Financial Positioning Justify Buy Rating

In a report released today, Ramsey El Assal from Barclays assigned a Buy rating to AvidXchange Holdings (AVDX – Research Report), with a price targ...

Barclays Gives a Buy Rating to AvidXchange Holdings (AVDX)

Wells Fargo analyst Andrew Bauch lowered the firm's price target on AvidXchange (AVDX) to $9 from $10 and keeps an Equal Weight rating on the share...

AvidXchange price target lowered to $9 from $10 at Wells Fargo

AMZN

ARES

ARKF

ARKK

ASML

ASMLF

AVDX

BBWI

BILL

BKNG

BPAY

BSQKZ

CPAY

EPAM

FDIG

GDDY

INTU

IPAY

JKHY

LPLA

MSFT

SMCI

SPOT

TOST

TSMWF

VRRM

WDAY

Legal

Press Releases

AVDX Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages AvidXchange Holdings, Inc. (NASDAQ: AVDX) Investors with Significant Losses to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AvidXchange Holdings, Inc. - AVDX

AvidXchange and Workamajig Announce Exclusive Strategic Partnership to Empower Media Companies to Manage Invoices Seamlessly

AVDX Investigation: Kessler Topaz Meltzer & Check, LLP Encourages AvidXchange Holdings, Inc. (NASDAQ: AVDX) Investors with Significant Losses to Contact the Firm

General

AvidXchange 2025 Trends Survey Reveals Finance Leaders' Top Priorities

AvidXchange Announces Timing of Its Third Quarter 2024 Financial Results Conference Call and Webcast

Free Career Event Returns to Charlotte, Bringing Hiring Experts and Resources to Job Seekers

Automation Drives Higher Career Satisfaction for Accounts Payable Professionals, New Survey Reveals

Comments

AvidXchange Holdings

AvidXchange Holdings (AVDX) Opzioni

AvidXchange Holdings (NASDAQ:AVDX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO